Evidence map›Paper›PMID 31709855›Full record

ReviewExpert opinion on therapeutic targets2019

Not the comfy chair! Cancer drugs that act against multiple active sites.

Laurence Booth, Andrew Poklepovic, Paul Dent

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on therapeutic targets, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Laurence BoothDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.
Andrew PoklepovicMedicine, Virginia Commonwealth University, Richmond, VA, USA.
Paul DentDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.
Virginia Commonwealth University · US

Funding

Pemetrexed and sildenafil for lung cancerR01CA192613 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENT, PAUL · 2015 to 2019
$1.6M
NCI NIH HHS R01 CA192613
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DevelopmentAnimalsAntineoplastic AgentsHumansNeoplasmsPrecision MedicineProtein Kinase InhibitorsProto-Oncogene MasSignal TransductionAntineoplastic AgentsMAS1 protein, humanProtein Kinase InhibitorsProto-Oncogene MasapoptosisAutophagychaperonedrugendoplasmic reticulumERKhistone deacetylasekinaseMAP kinaseneratiniboff-target effectpazopanibpemetrexedreceptor tyrosine kinasesorafenibsurvival signaling

Identifiers

PMID31709855
PMCPMC6892166
OpenAlexW2986417230

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.